Journal of Clinical Investigation,
Год журнала:
2021,
Номер
131(1)
Опубликована: Янв. 3, 2021
Carbohydrate
restriction,
used
since
the
1700s
to
prolong
survival
in
people
with
diabetes,
fell
out
of
favor
after
discovery
insulin.
Despite
costly
pharmacological
and
technological
developments
last
few
decades,
current
therapies
do
not
achieve
optimal
outcomes,
most
diabetes
remain
at
high
risk
for
micro-
macrovascular
complications.
Recently,
low-carbohydrate
diets
have
regained
popularity,
preliminary
evidence
benefit
body
weight,
postprandial
hyperglycemia,
hyperinsulinemia,
other
cardiometabolic
factors
type
2
and,
more
limited
data,
1
diabetes.
High-quality,
long-term
trials
are
needed
assess
safety
concerns
determine
whether
this
old
dietary
approach
might
help
attain
clinical
targets
effectively,
a
lower
cost,
than
conventional
treatment.
Alimentary Pharmacology & Therapeutics,
Год журнала:
2024,
Номер
59(S1)
Опубликована: Май 30, 2024
Summary
Background
The
current
obesity
pandemic
has
given
rise
to
associated
comorbidities
and
complications,
including
type
2
diabetes
metabolic
dysfunction‐associated
steatotic
liver
disease
(MASLD).
During
the
last
decade,
certain
glucagon‐like
peptide
1
receptor
agonists
(GLP‐1RA),
originally
developed
as
antihyperglycemic
drugs,
also
demonstrated
efficacy
for
weight
loss.
Aims
To
review
shared
pathophysiologic
features
of
common
diseases
compare
therapeutic
strategies
reduce
body
related
complications.
Methods
We
performed
an
extensive
literature
research
describe
effects
lifestyle
modification,
first‐generation
anti‐obesity
GLP‐1RA
on
loss
in
humans
with
obesity,
MASLD.
Results
Until
recently,
treatment
been
limited
which
offer
moderate
degree
sustainability
few
approved
drugs
are
either
short
term
use
or
forms
obesity.
Some
significantly
decrease
caloric
intake
weight.
Liraglutide
semaglutide
have
therefore
treating
people
They
lead
a
reduction
hepatic
fat
content
inflammation
biopsy‐confirmed
Possible
limitations
comprise
adverse
effects,
adherence
persistence.
Conclusion
Certain
superior
modification
inducing
markedly
changed
portfolio
additional
beneficial
disease.
The
global
prevalence
of
obesity
has
reached
epidemic
levels,
significantly
elevating
the
susceptibility
to
various
cardiometabolic
conditions
and
certain
types
cancer.
In
addition
causing
metabolic
abnormalities
such
as
insulin
resistance
(IR),
elevated
blood
glucose
lipids,
ectopic
fat
deposition,
can
also
damage
pancreatic
islet
cells,
endothelial
cardiomyocytes
through
chronic
inflammation,
even
promote
development
a
microenvironment
conducive
cancer
initiation.
Improper
dietary
habits
lack
physical
exercise
are
important
behavioral
factors
that
increase
risk
obesity,
which
affect
gene
expression
epigenetic
modifications.
Epigenetic
alterations
occur
in
early
stage
some
reversible,
while
others
persist
over
time
lead
obesity-related
complications.
Therefore,
dynamic
adjustability
modifications
be
leveraged
reverse
obesity-associated
diseases
interventions,
drugs,
bariatric
surgery.
This
review
provides
comprehensive
summary
impact
regulation
on
initiation
cancers,
type
2
diabetes,
cardiovascular
diseases,
establishing
theoretical
basis
for
prevention,
diagnosis,
treatment
these
conditions.
Food and Agricultural Immunology,
Год журнала:
2025,
Номер
36(1)
Опубликована: Янв. 16, 2025
The
Very
Low-Energy
Ketogenic
Therapy
(VLEKT)
is
a
structured,
multi-phase
dietary
regimen
characterized
by
carbohydrate
intake
of
less
than
50
g/day
and
daily
caloric
fewer
800
kcal,
which
induces
ketosis
facilitates
significant
weight
loss.
Evidence
suggests
that
this
nutritional
therapy
can
improve
glycemic
control,
lipid
profiles,
blood
pressure,
making
it
promising
option
for
managing
type
2
diabetes
(T2D)
reducing
cardiovascular
risk.
These
benefits
are
achieved
through
reductions
in
triglycerides
low-density
lipoprotein
cholesterol
(LDL-c),
alongside
increases
high-density
(HDL-c).
However,
the
effects
VLEKT
on
metabolism
remain
controversial.
review
emphasizes
urgent
need
further
research
to
validate
long-term
safety
efficacy
VLEKT.
It
also
highlights
critical
role
personalized
plans,
supervised
healthcare
professionals,
optimize
health
outcomes
address
individual
patient
needs.
Nutrients,
Год журнала:
2025,
Номер
17(6), С. 965 - 965
Опубликована: Март 10, 2025
With
the
prevalence
of
obesity
and
overweight
increasing
at
an
alarming
rate,
more
researchers
are
focused
on
identifying
effective
weight
loss
strategies.
The
ketogenic
diet
(KD),
used
as
a
treatment
in
epilepsy
management
for
over
100
years,
is
additionally
gaining
popularity
method.
Although
its
efficacy
well
documented,
areas
where
it
may
be
beneficial
to
other
dietary
approaches
need
carefully
examined.
objective
this
paper
identify
potential
benefits
KD
alternative
strategies
based
comprehensive
literature
review.
It
has
been
shown
that
bioenergetically
efficient
than
strategies,
inter
alia
owing
effect
curtailing
hunger,
improving
satiety
decreasing
appetite
(influence
hunger
hormones
sensation
hunger),
inducing
faster
initial
(associated
with
lower
glycogen
levels
reduced
water
retention),
controlling
glycaemia
insulinemia
(directly
attributable
low-carbohydrate
nature
indirectly
described).
These
effects
accompanied
by
improved
insulin
sensitivity,
inflammation
(through
ketone
bodies
avoidance
pro-inflammatory
sugars),
pharmacological
control
(the
diet’s
mechanisms
similar
those
medication
but
without
side
effects),
positive
impacts
psychological
factors
food
addiction.
Based
authors’
review
latest
research,
reasonable
conclude
that,
due
these
many
additional
health
benefits,
advantageous
diet-based
This
important
hypothesis
deserves
further
exploration,
which
could
achieved
including
outcome
measures
future
clinical
trials,
especially
when
comparing
different
diets
equal
caloric
value.
Journal of Clinical Investigation,
Год журнала:
2021,
Номер
131(1)
Опубликована: Янв. 3, 2021
Carbohydrate
restriction,
used
since
the
1700s
to
prolong
survival
in
people
with
diabetes,
fell
out
of
favor
after
discovery
insulin.
Despite
costly
pharmacological
and
technological
developments
last
few
decades,
current
therapies
do
not
achieve
optimal
outcomes,
most
diabetes
remain
at
high
risk
for
micro-
macrovascular
complications.
Recently,
low-carbohydrate
diets
have
regained
popularity,
preliminary
evidence
benefit
body
weight,
postprandial
hyperglycemia,
hyperinsulinemia,
other
cardiometabolic
factors
type
2
and,
more
limited
data,
1
diabetes.
High-quality,
long-term
trials
are
needed
assess
safety
concerns
determine
whether
this
old
dietary
approach
might
help
attain
clinical
targets
effectively,
a
lower
cost,
than
conventional
treatment.
